Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?

Graphical Abstract Graphical Abstract This figure illustrates three different approaches to the management of cardiomyopathies and of channelopathies. The first approach, on the left, reflects a currently growing trend and relies on the semi-passive acceptance of algorithms originated by ‘electronic risk calculators’ and ‘risk scores’: in this situation a non-expert physician, instead of deciding on his/her own, turns to and fully relies on the algorithm and this automated response predominantly favours the choice of ICD implant over alternative therapies. The second approach, in the middle, represents the wise combination of an experienced cardiologist using also the data from an electronic risk calculator and thereby considering all possible reasonable choices. The third approach, on the right, is the traditional one, based on the personal choice by an expert clinician who first integrates the specific characteristics of each patient and then makes an unbiased choice among the different therapeutic options available. The second and third approaches are equally valid; we wish to underscore that the third one implies that the ‘true expert’ does not need electronic risk calculators. By contrast, we regard as potentially dangerous the situation in which a doctor without specific expertise in uncommon and life-threatening disorders decides essentially on the sole basis of the algorithm. In all three approaches the final decision must be shared with the patient. Finally, after installing the initial therapy, risk stratification for SCD should be re-assessed on a regular basis during follow-up because the risk of SCD may change over time either increasing, due to the disease progression, or decreasing when the therapies are effective. The panel illustrating “Cardiac sympathetic denervation” is reproduced with permission from Collura et al.147

[1]  A. Shandilya,et al.  Sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2023, Disease-a-month : DM.

[2]  Stefan L. Zimmerman,et al.  A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy , 2022, European heart journal.

[3]  T. B. Rasmussen,et al.  Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2021, Journal of the American College of Cardiology.

[4]  W. Zareba,et al.  Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome. , 2021, Journal of the American College of Cardiology.

[5]  P. Postema,et al.  Brugada syndrome: update and future perspectives , 2021, Heart.

[6]  P. Schwartz,et al.  Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management. , 2021, JACC. Clinical electrophysiology.

[7]  Derick R. Peterson,et al.  Independent validation and clinical implications of the risk prediction model for long QT syndrome (1-2-3-LQTS-Risk). , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  P. Schwartz,et al.  Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. , 2021, European heart journal.

[9]  E. Ashley,et al.  Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. , 2021, European heart journal.

[10]  H. Calkins,et al.  Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  J. Roos‐Hesselink,et al.  Implantable loop recorders in patients with heart disease: comparison between patients with and without syncope , 2021, Open Heart.

[12]  J. Triedman,et al.  2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. , 2021, Heart rhythm.

[13]  D. Corrado,et al.  Arrhythmic risk stratification in arrhythmogenic cardiomyopathy: new predictors for left-sided variants? , 2021, European heart journal.

[14]  A. Zwinderman,et al.  Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction , 2021, European heart journal.

[15]  P. Schwartz,et al.  Precision Medicine and cardiac channelopathies: when dreams meet reality , 2021, European heart journal.

[16]  P. Delise Risk stratification in Brugada syndrome: the challenge of the grey zone. , 2021, European heart journal.

[17]  Stefan L. Zimmerman,et al.  Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy , 2020, Circulation. Arrhythmia and electrophysiology.

[18]  F. Sacher,et al.  Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome. , 2020, European heart journal.

[19]  M. Ackerman,et al.  Left Cardiac Sympathetic Denervation Monotherapy in Patients With Congenital Long QT Syndrome , 2020, Circulation. Arrhythmia and electrophysiology.

[20]  P. Schwartz 1970-2020: 50 years of research on the long QT syndrome-from almost zero knowledge to precision medicine. , 2020, European heart journal.

[21]  G. T. Gunnarsson,et al.  2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. , 2020, European heart journal.

[22]  P. Lambiase,et al.  Subcutaneous or Transvenous Defibrillator Therapy , 2020, New England Journal of Medicine.

[23]  M. Link,et al.  Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. , 2020, The American journal of cardiology.

[24]  P. Schwartz,et al.  Inherited cardiac arrhythmias , 2020, Nature Reviews Disease Primers.

[25]  B. Maron,et al.  Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. , 2020, Journal of the American College of Cardiology.

[26]  S. Colan,et al.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.

[27]  P. Sham,et al.  MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes , 2020, Cardiovascular research.

[28]  N. Sreeram,et al.  Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. , 2019, Heart rhythm.

[29]  J. Skinner,et al.  Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. , 2019, European heart journal.

[30]  B. Wessler,et al.  Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. , 2019, Circulation. Cardiovascular interventions.

[31]  K. Mandal,et al.  Cardiac sympathectomy for refractory ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy. , 2019, Heart Rhythm.

[32]  M. Link,et al.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.

[33]  E. Behr,et al.  Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry. , 2019, European heart journal.

[34]  P. Schwartz,et al.  Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. , 2019, Circulation. Arrhythmia and electrophysiology.

[35]  P. Schwartz,et al.  Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. , 2018, Heart rhythm.

[36]  D. Corrado,et al.  Sport activity in patients with implantable defibrillator: Playing with death? , 2018, European journal of preventive cardiology.

[37]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[38]  J. Healey,et al.  An autoantibody identifies arrhythmogenic right ventricular cardiomyopathy and participates in its pathogenesis , 2018, European heart journal.

[39]  P. Schwartz,et al.  Modifier genes for sudden cardiac death , 2018, European heart journal.

[40]  A. Abidov,et al.  Arrhythmogenic cardiomyopathy , 2018, The EACVI Textbook of Cardiovascular Magnetic Resonance.

[41]  B. Maron,et al.  Clinical Course and Management of Hypertrophic Cardiomyopathy , 2018, The New England journal of medicine.

[42]  R. Bellazzi,et al.  Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. , 2018, Journal of the American College of Cardiology.

[43]  S. Viskin Radiofrequency Ablation of Asymptomatic Brugada Syndrome: Don't Go Burning My Heart. , 2018, Circulation.

[44]  H. Calkins,et al.  Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2018, Circulation: Arrhythmia and Electrophysiology.

[45]  D. Lacroix,et al.  Catheter ablation reduces ventricular tachycardia burden in patients with arrhythmogenic right ventricular cardiomyopathy: insights from a north-western French multicentre registry , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[46]  Jian Zhang,et al.  Long-Term Prognosis after Myectomy in Hypertrophic Obstructive Cardiomyopathy with Severe Left Ventricular Hypertrophy , 2018, Cardiology.

[47]  L. Eckardt,et al.  Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults. , 2017, JACC. Clinical electrophysiology.

[48]  A. Keren,et al.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.

[49]  H. Calkins,et al.  Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy , 2017, Circulation.

[50]  D. Judge,et al.  Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis , 2017, Cardiovascular research.

[51]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[52]  Marmar Vaseghi,et al.  Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. , 2017, Journal of the American College of Cardiology.

[53]  P. Brugada,et al.  A score model to predict risk of events in patients with Brugada Syndrome , 2017, European heart journal.

[54]  Toshihiro Tanaka,et al.  Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry , 2017, Circulation.

[55]  A. von Eckardstein,et al.  Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome , 2017, European heart journal.

[56]  J. Brugada,et al.  Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome , 2017, Circulation. Arrhythmia and electrophysiology.

[57]  M. Link,et al.  Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.

[58]  G. Hindricks,et al.  Should all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergo epicardial catheter ablation? , 2017, Journal of Interventional Cardiac Electrophysiology.

[59]  M. Link,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. , 2017, Journal of the American College of Cardiology.

[60]  M. Link,et al.  Arrhythmogenic Right Ventricular Cardiomyopathy. , 2017, The New England journal of medicine.

[61]  A. Wilde,et al.  Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. , 2016, Journal of the American College of Cardiology.

[62]  B. Belhassen Management of Brugada Syndrome 2016: Should All High Risk Patients Receive an ICD? Alternatives to Implantable Cardiac Defibrillator Therapy for Brugada Syndrome. , 2016, Circulation. Arrhythmia and electrophysiology.

[63]  H. Huikuri,et al.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge , 2016, Journal of arrhythmia.

[64]  S. Khalsa,et al.  Clinical neurocardiology defining the value of neuroscience‐based cardiovascular therapeutics , 2016, The Journal of physiology.

[65]  D. Corrado,et al.  Implantable cardioverter defibrillator therapy in young patients with cardiomyopathies and channelopathies: a single Italian centre experience , 2016, Journal of cardiovascular medicine.

[66]  K. Shivkumar,et al.  Role of Bilateral Sympathectomy in the Treatment of Refractory Ventricular Arrhythmias in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. , 2016, Circulation. Arrhythmia and electrophysiology.

[67]  D. Corrado,et al.  Relationship Between Arrhythmogenic Right Ventricular Cardiomyopathy and Brugada Syndrome: New Insights From Molecular Biology and Clinical Implications , 2016, Circulation. Arrhythmia and electrophysiology.

[68]  D. Lin,et al.  Long-Term Outcome With Catheter Ablation of Ventricular Tachycardia in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy , 2015, Circulation. Arrhythmia and electrophysiology.

[69]  P. Ellinor,et al.  Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis , 2016, Circulation.

[70]  Pier D. Lambiase,et al.  The learning curve associated with the introduction of the subcutaneous implantable defibrillator , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[71]  M. Link,et al.  Treatment of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2015, Circulation.

[72]  P. Brugada,et al.  Prognostic Value of Programmed Electrical Stimulation in Brugada Syndrome: 20 Years Experience , 2015, Circulation. Arrhythmia and electrophysiology.

[73]  M. Link,et al.  Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement , 2015, European heart journal.

[74]  P. Schwartz,et al.  Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. , 2015, Circulation.

[75]  P. Brugada,et al.  Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. , 2015, Journal of the American College of Cardiology.

[76]  T. Edvardsen,et al.  Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members , 2014, European journal of heart failure.

[77]  P. Schwartz,et al.  AKAP9 Is a Genetic Modifier of Congenital Long-QT Syndrome Type 1 , 2014, Circulation. Cardiovascular genetics.

[78]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[79]  M. Link,et al.  Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment. , 2014, Journal of the American College of Cardiology.

[80]  D. Pennell,et al.  Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy , 2014, Heart.

[81]  P. Schwartz Cardiac sympathetic denervation to prevent life-threatening arrhythmias , 2014, Nature Reviews Cardiology.

[82]  S. Priori,et al.  Novel Insight Into the Natural History of Short QT Syndrome , 2014, Journal of the American College of Cardiology.

[83]  L. Held,et al.  Different Prognostic Value of Functional Right Ventricular Parameters in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2014, Circulation. Cardiovascular imaging.

[84]  D. Corrado,et al.  Compound and Digenic Heterozygosity Predicts Lifetime Arrhythmic Outcome and Sudden Cardiac Death in Desmosomal Gene–Related Arrhythmogenic Right Ventricular Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[85]  C. Tracy,et al.  HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. , 2013, Heart rhythm.

[86]  Michael J Ackerman,et al.  The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. , 2013, European heart journal.

[87]  S. Russell,et al.  Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. , 2013, Journal of the American College of Cardiology.

[88]  L. Jordaens,et al.  Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. , 2013, American heart journal.

[89]  P. Schwartz,et al.  Identification of a KCNQ1 Polymorphism Acting as a Protective Modifier Against Arrhythmic Risk in Long-QT Syndrome , 2013, Circulation. Cardiovascular genetics.

[90]  M. Link,et al.  Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry , 2013, Circulation.

[91]  A. Bassett,et al.  The natural history of a genetic subtype of arrhythmogenic right ventricular cardiomyopathy caused by a p.S358L mutation in TMEM43 , 2013, Clinical genetics.

[92]  Wataru Shimizu,et al.  Long-term follow-up of a pediatric cohort with short QT syndrome. , 2013, Journal of the American College of Cardiology.

[93]  Thomas Meitinger,et al.  Calmodulin Mutations Associated With Recurrent Cardiac Arrest in Infants , 2013, Circulation.

[94]  C. Poggesi,et al.  Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy , 2013, Circulation.

[95]  Arthur A M Wilde,et al.  The ICD for Primary Prevention in Patients With Inherited Cardiac Diseases: Indications, Use, and Outcome: A Comparison With Secondary Prevention , 2013, Circulation. Arrhythmia and electrophysiology.

[96]  D. Corrado,et al.  Prognostic Value of Endocardial Voltage Mapping in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2013, Circulation. Arrhythmia and electrophysiology.

[97]  S. Russell,et al.  Risk Stratification in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy–Associated Desmosomal Mutation Carriers , 2012, Circulation. Arrhythmia and electrophysiology.

[98]  R. Hauer,et al.  Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. , 2012, Journal of the American College of Cardiology.

[99]  A. Leenhardt,et al.  The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[100]  M. Ackerman,et al.  Videoscopic Left Cardiac Sympathetic Denervation for Patients With Recurrent Ventricular Fibrillation/Malignant Ventricular Arrhythmia Syndromes Besides Congenital Long-QT Syndrome , 2012, Circulation. Arrhythmia and electrophysiology.

[101]  S. Priori,et al.  [Risk stratification in Brugada syndrome]. , 2011, Giornale italiano di cardiologia.

[102]  S. Russell,et al.  Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. , 2011, Journal of the American College of Cardiology.

[103]  Andrea Mazzanti,et al.  Long-term follow-up of patients with short QT syndrome. , 2011, Journal of the American College of Cardiology.

[104]  A. Wilde,et al.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. , 2011, Journal of the American College of Cardiology.

[105]  L. Mestroni,et al.  Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. , 2011, European heart journal.

[106]  Tachapong Ngarmukos,et al.  Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract Epicardium , 2011, Circulation.

[107]  B. Gersh,et al.  Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[108]  L. Jordaens,et al.  Who Are the Long-QT Syndrome Patients Who Receive an Implantable Cardioverter-Defibrillator and What Happens to Them?: Data From the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry , 2010, Circulation.

[109]  M. Link,et al.  Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia , 2010, Circulation.

[110]  P. Schwartz Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: medicolegal complications. , 2010, Heart rhythm.

[111]  P. Schwartz,et al.  Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. , 2010, Heart rhythm.

[112]  M Borggrefe,et al.  Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry , 2010, Circulation.

[113]  P. Schwartz,et al.  NOS1AP Is a Genetic Modifier of the Long-QT Syndrome , 2009, Circulation.

[114]  E. Kaufman,et al.  Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. , 2009, Journal of the American College of Cardiology.

[115]  G. Marcus,et al.  Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. , 2009, Journal of the American College of Cardiology.

[116]  P. Schwartz Cutting nerves and saving lives. , 2009, Heart rhythm.

[117]  M. Ackerman,et al.  Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. , 2009, Heart rhythm.

[118]  A. Leenhardt,et al.  Incidence and Risk Factors of Arrhythmic Events in Catecholaminergic Polymorphic Ventricular Tachycardia , 2009, Circulation.

[119]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[120]  M. Gollob,et al.  Sudden Death in a Young Man with Catecholaminergic Polymorphic Ventricular Tachycardia and Paroxysmal Atrial Fibrillation , 2008, Journal of cardiovascular electrophysiology.

[121]  P. Schwartz,et al.  Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. , 2008, The New England journal of medicine.

[122]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[123]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[124]  Andrew J. Sauer,et al.  Long QT syndrome in adults. , 2007, Journal of the American College of Cardiology.

[125]  A. Krahn,et al.  Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. , 2006, Heart rhythm.

[126]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[127]  Lauri Toivonen,et al.  The Jervell and Lange-Nielsen Syndrome: Natural History, Molecular Basis, and Clinical Outcome , 2006, Archives des maladies du coeur et des vaisseaux.

[128]  Dan M Roden,et al.  KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome , 2005, Circulation.

[129]  C. Autore,et al.  The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. , 2005, Journal of the American College of Cardiology.

[130]  Arthur J Moss,et al.  25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome. , 2005, Circulation.

[131]  X. Jouven,et al.  Natural History and Risk Stratification of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy , 2004, Circulation.

[132]  S. Priori,et al.  CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism , 2004, Cell.

[133]  S. Viskin,et al.  Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome , 2004, Circulation.

[134]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[135]  M. Sanguinetti,et al.  Compound Mutations: A Common Cause of Severe Long-QT Syndrome , 2004, Circulation.

[136]  G. Breithardt,et al.  Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy: Single-Center Experience of Long-Term Follow-Up and Complications in 60 Patients , 2004, Circulation.

[137]  M. Link,et al.  Implantable Cardioverter-Defibrillator Therapy for Prevention of Sudden Death in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia , 2003, Circulation.

[138]  J. Brugada,et al.  Determinants of Sudden Cardiac Death in Individuals With the Electrocardiographic Pattern of Brugada Syndrome and No Previous Cardiac Arrest , 2003, Circulation.

[139]  Carlo Napolitano,et al.  How Really Rare Are Rare Diseases?: , 2003, Journal of cardiovascular electrophysiology.

[140]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[141]  Carlo Napolitano,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[142]  Derick R. Peterson,et al.  Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel , 2002, Circulation.

[143]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[144]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[145]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[146]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[147]  S. Priori,et al.  Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. , 1998, The New England journal of medicine.

[148]  S. Priori,et al.  Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. , 1995, Circulation.

[149]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.

[150]  A. Moss,et al.  Left Cardiac Sympathetic Denervation in the Therapy of Congenital Long QT Syndrome: A Worldwide Report , 1991, Circulation.

[151]  D. Corrado,et al.  Right ventricular cardiomyopathy and sudden death in young people. , 1988, The New England journal of medicine.

[152]  P. Schwartz The idiopathic long QT syndrome: the need for a prospective registry. , 1983, European heart journal.

[153]  H. L. Stone,et al.  Left stellectomy and denervation supersensitivity in conscious dogs. , 1982, The American journal of cardiology.

[154]  H. L. Stone,et al.  Effects of Unilateral Stellectomy upon Cardiac Performance during Exercise in Dogs , 1979, Circulation research.

[155]  H. L. Stone,et al.  Tonic influence of the sympathetic nervous system on myocardial reactive hyperemia and on coronary blood flow distribution in dogs. , 1977, Circulation research.

[156]  P. Schwartz,et al.  Effect of Stellectomy and Vagotomy on Ventricular Refractoriness in Dogs , 1977, Circulation research.

[157]  A. Malliani,et al.  The long Q-T syndrome. , 1975, American heart journal.

[158]  A. Moss,et al.  Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. , 1971, The New England journal of medicine.

[159]  OUP accepted manuscript , 2022, European Heart Journal.

[160]  P. Schwartz,et al.  Long and Short QT Syndromes , 2018 .

[161]  William J. Bryant,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[162]  P. Schwartz When the risk is sudden death, does quality of life matter? , 2016, Heart rhythm.

[163]  M. Ackerman,et al.  Quality of life after videoscopic left cardiac sympathetic denervation in patients with potentially life-threatening cardiac channelopathies/cardiomyopathies. , 2016, Heart rhythm.

[164]  H. Huikuri,et al.  J-Wave syndromes expert consensus conference report: Emerging concepts and gaps in knowledge. , 2016, Heart rhythm.

[165]  KoonlaweeNademanee,et al.  Prevention of Ventricular Fibrillation Episodes in Brugada Syndrome by Catheter Ablation Over the Anterior Right Ventricular Outflow Tract Epicardium , 2011 .

[166]  J. Graham Clinical Implications for Patients With Long QT Syndrome Who Experience a Cardiac Event During Infancy , 2010 .

[167]  P. Schwartz,et al.  All LQT3 patients need an ICD: true or false? , 2009, Heart rhythm.

[168]  M. Bitner-Glindzicz,et al.  The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. , 2006, Circulation.

[169]  A. Moss,et al.  The long QT syndrome: a prospective international study. , 1985, Circulation.

[170]  P. Schwartz,et al.  Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. , 1976, The American journal of cardiology.

[171]  A Malliani,et al.  Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. , 1975, American heart journal.